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Summary. Background: Patients undergoing bariatric surgery are at moderate to high risk of venous thromboembolism (VTE). The optimal dose and duration of anticoagulant prophylaxis is uncertain. Objective: To evaluate the safety of extended-duration weight-adjusted tinzaparin after bariatric surgery. Patients/methods: We conducted a single-center retrospective cohort study of consecutive patients undergoing bariatric surgery who received weight-adjusted tinzaparin 4500-14 000 IU daily (75 IU kg À1 rounded to the nearest prefilled syringe) for
Introduction
Bariatric surgery is an effective intervention for producing sustained weight reduction in obese patients and, currently, is the second most common surgical procedure performed in North America [1] . Patients undergoing bariatric surgery are at moderate to high risk of venous thromboembolism (VTE), which comprises deep vein thrombosis (DVT) and pulmonary embolism (PE), because of associated risk factors that include obesity, perioperative venous stasis and hypercoagulability [2] . The median incidence of postoperative symptomatic VTE, fatal PE and major bleeding is 2.4%, 0.3% and 1.3%, respectively, but reported estimates vary widely, probably because of across study heterogeneity in patient characteristics, surgery types and VTE prophylaxis regimens administered [3, 4] . PE is the most frequently reported cause of postoperative mortality, representing 30% of deaths within 30 days of surgery, with most events occurring after hospital discharge (median 14 days) [5, 6] . The optimal pharmacologic VTE prophylaxis strategy after bariatric surgery is uncertain and needs to address the dose and duration of anticoagulants. In general, studies assessing prophylaxis with low-molecular-weight heparin (LMWH) after bariatric surgery demonstrate variable VTE rates between 0% and 5.4%; such variability in VTE rates probably reflects differences in LMWH dose regimens administered (fixed vs. weight-adjusted), the duration of prophylaxis (inpatient vs. extended outpatient), and outcomes assessed (asymptomatic vs. symptomatic VTE) [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Similarly, rates of major bleeding with LMWH prophylaxis also vary widely, between 0% and 6.7% [17] .
As the majority of postoperative VTEs occur following hospital discharge, extension of prophylaxis to the outpatient setting has been proposed. A small prospective study demonstrated a reduction (0% vs. 4.5%) in out-ofhospital VTEs in patients receiving 10 days of post-discharge enoxaparin compared with enoxaparin in-hospital alone [14] . A larger prospective cohort study demonstrated that up to 3 weeks of prophylactic dalteparin was safe and effective in reducing VTE [13] . Other studies using 10-30 days of prophylaxis suggest that extended durations are effective, although the data are observational and with small numbers of patients [10, 15, 18] .
An issue relevant to bariatric surgery is whether to use a weight-adjusted dose of LMWH prophylaxis instead of a fixed, low-dose LMWH regimen, which may result in an inadequate anticoagulant effect [19, 20] . In a meta-analysis of 19 observational studies, it was concluded that the incidence of major bleeding appeared to increase using weight-adjusted doses of heparin or LMWH, with no advantage for VTE reduction [21] . A more recent metaanalysis of six prospective studies that used weight-based prophylaxis, totaling 1858 patients, suggested that weightadjusted prophylaxis conferred a lower rate of in-hospital VTE after bariatric surgery than a fixed, low-dose regimen, without increasing major bleeding [17] . Meanwhile, a prospective study with tinzaparin demonstrated that antiXa activity is independent of body weight when weightbased dosing is used in obese patients, suggesting that weight-based dosing is appropriate [22] .
Against this background, we retrospectively assessed rates of VTE and major bleeding occurring in association with 10 days of a standardized, weight-adjusted, tinzaparin-based VTE prophylaxis strategy after bariatric surgery. As part of a prespecified quality control initiative, data were collected prospectively on patients who had bariatric surgery at our hospital from 2009 to 2012. Its aim was to assess the safety of this standardized weightadjusted, tinzaparin-based VTE prophylaxis strategy, as defined by (i) postoperative rates of VTE and major bleeding outcomes and (ii) trough anticoagulant levels after 5-10 days of prophylaxis. Herein, we provide an analysis of the safety of this standardized VTE prophylaxis strategy in a large cohort of patients who had bariatric surgery.
Methods

Patient population
This study was conducted at St. Joseph's Healthcare Hamilton, Hamilton, Canada, which is a regional referral center for bariatric surgery and performs 300-400 bariatric procedures annually. Patients were eligible to receive the standardized VTE prophylaxis strategy if they were ≥ 18 years of age, with a body mass index (BMI) ≥ 30 kg m À2 , and were scheduled to undergo primary or revisional bariatric surgery under general anesthesia with one of the following procedures: Roux-en-Y gastric bypass, sleeve gastrectomy, biliopancreatic diversion or duodenal switch. Patients were not eligible to receive the standardized prophylaxis if they were already receiving full-dose anticoagulant therapy, had VTE within the past 3 months, or had a creatinine clearance ≤ 20 mL min
À1
. The study received approval from the Institutional Review Board and was conducted in accordance with local research ethics and patient confidentiality policies.
Study design
Our hospital implemented a standardized, weightadjusted, tinzaparin-based, prophylaxis protocol for bariatric surgery in 2009. As part of a quality control initiative, data were prospectively collected on patients who received this prophylaxis strategy in order to assess patient safety, as this management was deemed empiric. For this analysis, we performed a retrospective review of consecutive patients who had bariatric surgery at our center between July 2009 and December 2012, for whom inhospital and, where available, 30-day postoperative data and trough anti-factor Xa levels were collected as part of the quality control initiative. All patients were assessed preoperatively with documentation of baseline demographics, body weight, BMI, concurrent medical problems and medication use. Additional patient data regarding hormonal therapy use, prior VTE and non-steroid antiinflammatory medication use were collected via a structured, centralized review of electronic medical records and clinic records. Outcomes were recorded while patients were in hospital and at a regularly scheduled follow-up visit 30 days after surgery. Missing values were reported as unknowns. A subset of patients who were referred from other hospitals only had in-hospital data collected because outpatient follow-up occurred at their local site.
Standardized VTE prophylaxis regimen
All patients undergoing bariatric surgery who satisfied the eligibility criteria received the following standardized VTE prophylaxis regimen. Just before surgery, patients received a single dose of subcutaneous unfractionated heparin (UFH), 5000 or 7500 IU. On the evening after surgery, patients received either no pharmacologic prophylaxis or an additional dose of subcutaneous UFH, 5000 or 7500 IU, at the surgical team's discretion. Patients also received intraoperative pneumatic compression devices.
Starting on postoperative day 1, patients received weight-adjusted tinzaparin for 10 days (1-3 days of inpatient treatment, 7-9 days of outpatient treatment) at a dose of 75 IU/kg daily, rounded to the nearest prefilled syringe. For weight < 110 kg, patients received 4500 IU daily; for 110-159 kg, 10 000 IU daily; and for 160 kg or greater, 14 000 IU daily. The 4500 IU, 10 000 IU and 14 000 IU doses were chosen as they were the commercially available prefilled syringe sizes at the time of the program's inception. Prophylaxis was discontinued in patients with signs of clinically overt bleeding that was considered, by the surgical team, as greater than expected. An early mobilization program was initiated in all patients. Following discharge from hospital, patients underwent routine follow-up in the Bariatric Clinic at 1 week and 1 month after surgery. To assess for potential bioaccumulation of tinzaparin, trough anti-factor Xa levels were measured 5-10 days after surgery in those patients who returned for follow-up and who had not already taken that day's tinzaparin dose (to enable trough anticoagulant level measurement). The anti-factor Xa level was not used to decide whether to continue or stop anticoagulant prophylaxis as the result was available 4-7 days after testing and the intent was that all patients were to receive a 10-day course of prophylaxis.
Study outcomes and analysis
A primary (30-day) assessment of safety outcomes (VTE, major bleeding) was carried out for patients who had inhospital and 30-day follow-up at the bariatric clinic. A secondary (in-hospital only) assessment of safety outcomes was carried out for patients during the in-hospital period after surgery; this included 393 patients whose follow-up occurred at peripheral referral sites.
Venous thromboembolism was defined as any objectively confirmed, symptomatic DVT, PE or splanchnic vein thrombosis that occurred within 30 days of surgery in patients who received at least one dose of tinzaparin. Objective confirmation of VTE was based on compression ultrasonography for DVT, computed tomography pulmonary angiography (CT-PA) or nuclear ventilation-perfusion (V/Q) lung scan for PE, and CT scan or Duplex ultrasound for splanchnic vein thrombosis.
Major bleeding was defined as clinically overt bleeding that occurred within 30 days of surgery, based on the International Society for Thrombosis and Haemostasis (ISTH) criteria, which required [23] one or more of: (i) fatal bleeding; (ii) symptomatic bleeding in a critical area or organ; (iii) extra-surgical site bleeding with temporal association (24-48 h) to a fall in hemoglobin of ≥ 20 g L À1 or transfusion of ≥ 2 units of whole blood or red cells; or (iv) surgical site bleeding requiring intervention, or unexpected/prolonged bleeding and/or causing hemodynamic instability. When possible, trough anti-factor Xa levels were measured after 5-10 days of tinzaparin prophylaxis during a scheduled follow-up visit. Statistical analysis was performed using SPSS version 25.0 (SPSS Inc., Apache Software Foundation, Chicago, IL, USA). Descriptive statistics were reported as medians and interquartile ranges (IQR) for continuous variables, and as proportions for categorical variables.
Results
Patient characteristics and VTE prophylaxis
A total of 1279 patients were scheduled for bariatric surgery at our center between July 2009 and December 2012 (see flow chart in Fig. 1 ). Of these, 67 (5.2%) patients were excluded because of a need for therapeutic-dose anticoagulation (n = 21), cancelled surgery (n = 7), non-administration of tinzaparin after surgery due to intraoperative/immediate postoperative bleeding (n = 18), or platelet dysfunction/ thrombocytopenia (n = 4). The reason for tinzaparin omission was unspecified in 17 patients. Baseline characteristics for the 39 excluded patients who underwent surgery and who did not require therapeutic anticoagulation did not differ substantively from patients who received the prophylaxis regimen (Table S1 ).
The primary safety analysis was limited to 819 patients who were assessed for in-hospital outcomes and who had a 30-day follow-up at the same hospital as their surgery. An additional 393 patients were included in the secondary safety analysis of in-hospital outcomes only, as their follow-up occurred at a different (referring) hospital and obtaining follow-up data was not feasible. In total, 1212 patients were assessed for in-hospital outcomes. There were no patients lost to follow-up among those who had follow-up at the same hospital as their surgery.
Patient characteristics are shown in Table 1 . Gastric bypass surgery and sleeve gastrectomy were the most common procedures (78.3% and 20.5%, respectively). Median body weight was 130.0 kg, with 28 patients (2.3%) > 200 kg. Hormonal therapy was used in 7.8% patients at baseline and 2.4% had a history of VTE. There were no substantive differences in baseline characteristics between 819 patients who had complete 30-day follow-up and the 393 patients for whom in-hospital outcomes only were reported.
Tinzaparin dosing is displayed in Table 1 . The first dose of weight-adjusted tinzaparin was administered on postoperative day 1 in 1152 (95.0%) patients at a median (IQR) of 1.0 (1.0-1.0) days. Postoperative non-steroidal anti-inflammatory drug use was documented in 30.7% of patients.
VTE outcomes
As shown in Table 2 , after 30-day follow-up, 4/819 patients (0.5%) developed symptomatic VTE within 30 days of surgery, including PE (n = 3) and superior mesenteric vein thrombosis (n = 1); there was no fatal PE during the follow-up period. In regard to in-hospital VTE events, this occurred in 3/1212 (0.2%), all of which were PE occurring 1-5 days after surgery. Two of these events were included in the primary safety analysis above. One PE occurred in a patient who weighed 229 kg who was receiving tinzaparin 14 000 IU daily. Although the CT- PA was inconclusive, he received empiric anticoagulation because of hypoxia with elevated pulmonary pressures on conventional pulmonary angiography.
Bleeding outcomes
As shown in Table 3 , in the primary safety analysis major bleeding occurred in 13/819 patients (1.6%) within 30 days of surgery. These bleeding events all occurred during the surgical hospital admission. In the secondary safety analysis of all patients followed until hospital discharge only, there were 22 major bleeding events among 1212 patients (1.8%). All major bleeding events occurred at gastrointestinal or surgical sites. Non-major bleeding occurred in 24/819 (2.9%) patients who completed 30-day follow-up, and 22/1212 (1.8%) of the entire patient group in-hospital only. In the primary safety analysis, nonmajor bleeding was predominantly gastrointestinal (n = 10/24) or surgical site (n = 12/24), with one case each of hematuria and epistaxis.
Anti-factor Xa activity levels
Trough anti-factor Xa activity was measured in a subset of 187 patients at a median (IQR) of 6.0 (4.0-8.0) days of tinzaparin treatment in whom blood testing was feasible. All patients had anti-factor Xa levels of ≤ 0.40 IU mL À1 , with 74.8% having undetectable activity (< 0.10 IU mL À1 ) and 23.0% with activity between 0.10 and 0.20 IU mL À1 . As shown in Table 4 , there were no differences in trough anti-factor Xa activity in patients receiving the higher doses of prophylaxis.
Discussion
In this cohort of patients undergoing bariatric surgery, a standardized thromboprophylaxis regimen consisting of 10 days of weight-adjusted tinzaparin starting on day 1 after surgery was associated with low 30-day postoperative rates of symptomatic VTE (0.5%) and major bleeding (1.6%), coupled with no pharmacokinetic evidence of drug accumulation. These findings suggest that 10 days of weight-adjusted tinzaparin is a safe strategy for VTE prophylaxis after bariatric surgery. These results are consistent with other studies suggesting that weight-adjusted LMWH-based VTE prophylaxis may be more efficacious than a fixed, lower-dose LMWH regimen after bariatric surgery. The optimal dose of LMWH after bariatric surgery is unclear, with smaller randomized trials suggesting that adjusting for weight does not significantly reduce the risk of postoperative VTE [9, 16] . However, a meta-analysis totaling 1858 patients found that patients receiving weight-adjusted prophylaxis with UFH or LMWH had a lower rate of in- hospital VTE compared with fixed lower-dose regimens (0.5% vs. 2.0%), with similar rates of major bleeding (1.6% vs. 2.3%) [17] . Similar rates of postoperative symptomatic VTE (0.6%) and major bleeding (2.0%) were found in another meta-analysis that included three studies with weight-based heparin prophylaxis [21] . These data are also supported by pharmacokinetic studies suggesting that higher doses of LMWH prophylaxis in hospitalized obese patients lead to a favorable anticoagulant effect, as measured by anti-factor Xa levels [24] . Our data further support these findings by demonstrating low rates of VTE and postoperative bleeding in our patient cohort. Our findings also support the premise that extended prophylaxis beyond the in-hospital period appears to be safe and feasible. Most VTE events after bariatric procedures occur after discharge from hospital, providing the rationale for extended duration prophylaxis, especially as patients are now discharged within 48 h (often the same day) after bariatric surgery [3, 5, 6, 14] . Reassuringly, despite using doses of tinzaparin exceeding usual prophylaxis doses, there did not appear to be evidence of excessive anti-factor Xa anticoagulant activity after 1 week, nor higher rates of major bleeding compared with other studies that assessed extended prophylaxis with fixed, lower-dose regimens. One patient in our cohort sustained thrombosis of the superior mesenteric vein at 26 days after surgery, which is an uncommon but recognized complication of laparoscopic bariatric procedures [25, 26] .
Our findings have practical implications for the prevention of VTE after bariatric surgery. By using a simple © 2018 International Society on Thrombosis and Haemostasis weight-adjusted, once-daily tinzaparin-based VTE prophylaxis protocol, we demonstrated postoperative VTE rates that appear similar to or lower than those in cohort studies in which weight-based dosing was not used [27, 28] . The feasibility and efficacy of pharmacologic prophylaxis extended out of hospital have also been demonstrated in other high-risk patient groups, including medical inpatients and colorectal cancer surgery [29, 30] . In our study, only one patient developed non-fatal PE following discharge, suggesting that the use of extended prophylaxis led to a reduction in VTE occurring out of hospital. By contrast, most bleeding events occurred early in the postoperative course, with bleeding at surgical sites. The rate of major bleeding was similar to rates in studies using standard fixed doses, suggesting that the use of weight adjustment may not substantively increase the risk of bleeding. Strengths of our study included its large sample size, the availability of trough anti-factor Xa activity levels in a subgroup of patients, and its focus on detecting symptomatic VTE events. There were also limitations in this retrospective study. First, we lacked a control group using fixed doses or limited duration of prophylaxis for comparison. Second, we did not collect data concerning other VTE risk factors after bariatric surgery, including the duration of the procedure, smoking or intraoperative surgical complexity [3] . The administration and dosing of subcutaneous UFH pre-and postoperatively were not standardized. Third, 30-day follow-up was not available in approximately one-third of patients who had been referred from outside centers where follow-up would have taken place. We chose to include these patients in our quality control initiative to capture all safety outcomes during the in-hospital period. We acknowledge that patients who were referred from outside sites and only had in-hospital follow-up may have had different rates of adverse outcomes. However, we think this is unlikely because the characteristics and types of procedures of patients who did or did not have 30-day follow-up did not appear to differ (Table 1) . Finally, given the limitations of this study's retrospective design, validation of this weight-based approach in a prospective management study is warranted.
In conclusion, this study provides evidence for the safety of extended thromboprophylaxis with weightadjusted tinzaparin after bariatric surgery. The dosing protocol used in this real-world study demonstrates low rates of VTE and major bleeding. Given the moderate to high risk of postoperative VTE in this surgical population, this approach should be considered in bariatric centers for routine thromboprophylaxis. Crowther were involved in the study's concept and design, and in critical writing and manuscript review. D. Siegal was involved in concept and design, data analysis, data interpretation and manuscript review. All authors approved the final version.
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